期刊文献+

胰腺癌质子调强与光子容积旋转调强计划的剂量学比较 被引量:1

Comparisons of dose distributions between IMPT and VMAT for pancreatic cancer
原文传递
导出
摘要 目的比较质子调强和光子容积旋转调强在胰腺癌大分割放射治疗计划中的剂量学差异。方法回顾性选取10例胰腺癌患者临床资料,分别使用Eclipse和RayStation进行容积旋转调强治疗(VMAT)和质子调强治疗(IMPT)的计划设计。完成计划后的剂量文件统一导入MIM软件以提取评估参数。主要评估参数包括计划靶区(PTV)的D_(min)、D_(mean)、D_(max)、适形指数(CI)和新适形指数(nCI)、均匀指数(HI)、梯度指数(GI)、覆盖率(coverage)和危及器官的受照剂量。结果靶区方面两组的适形性差异无统计学意义(P>0.05),VMAT组取得了更高的PTV D_(min)、D_(max)、D98%、D2%、HI和覆盖率以及更优的剂量梯度GI和D2 cm(t/Z=-4.63~5.32,P<0.05),IMPT组则获得了更低的10%_PD(t=-7.47,P<0.05)。危及器官方面,两组的空回肠最大剂量D_(max)、胃D_(max)、十二指肠D_(max)以及左肾的平均剂量D_(mean)差异无统计学意义(P>0.05)。IMPT组在空回肠的体积剂量D_(5 cm^(3))、胃的D_(10 cm^(3))、十二指肠的D_(5 cm^(3))及D_(10 cm^(3))、左肾的D_(2/3)、右肾的D_(mean)及D_(2/3)上均低于VMAT组(t/Z=-8.12~-2.60,P<0.05),但是IMPT组脊髓的D_(max)和D_(0.35 cm^(3))均高于VMAT组(t=7.30、6.77,P<0.05)。结论VMAT和IMPT都能实现满足临床要求的胰腺癌大分割放射治疗计划。二者在在毗邻胰腺靶区的胃肠道组织最大受量上的保护无差异,在胃肠道的体积受量保护上IMPT拥有更大优势,但对射束肿瘤靶区前缘的危及器官保护上可能弱于VMAT。 Objective To compare dose distributions of hypofractionated radiotherapy for pancreatic cancer between IMPT and VMAT.Methods Ten pancreatic cancer cases were included in this retrospective study.Photon(Edge)and proton(Proteus®PLUS)plans were designed by Eclipse and RayStation TPS,respectively.All plans were transferred to MIM system for extraction of parameters,which included D_(min),D_(mean)and D_(max)of PTV,conformity index(CI),new conformity index(nCI),homogeneity index(HI),gradient index(GI),coverage,D_(max)and dose-volume of the organs at risk(OARs).Results There was no significant difference in CI between the two groups.The higher PTV D_(min),D_(mean),D_(max),D98%,D2%,HI,coverage and the better GI,D2 cmwere found in VMAT(t/Z=-4.63-5.32,P<0.05).The lower 10%_PD was found in IMPT(t=-7.47,P<0.05).Regarding the OARs,D_(max)of the intestine,stomach,and duodenum and D_(mean)of the left kidney were similar between two groups without significant difference(P>0.05).The D_(5 cm^(3))of the intestine,D_(10 cm^(3))of the stomach,D_(5 cm^(3))and D_(10 cm^(3))of the duodenum,D_(2/3)of the left kidney,D_(mean)and D_(2/3)of the right kidney were lower in IMPT than those in VMAT(t/Z=-8.12--2.60,P<0.05).However,the D_(max)and D_(0.35 cm^(3))of the spinal cord were higher in IMPT than those in VMAT(t=7.30,6.77,P<0.05).Conclusions Both of hypofractionated radiotherapy plans of pancreatic cancer designed by VMAT and IMPT could meet clinical needs.No significant difference was found in D_(max)of the adjacent gastrointestinal tracts between the two groups.While IMPT had the advantage over VMAT in the case of lower dose-volumes of the gastrointestinal tracts.Nevertheless,less protections of the OARs in front of the tumor volume could be provided by IMPT compared with VMAT.
作者 曹洋森 李左峰 徐宁 郭晓晶 张火俊 Cao Yangsen;Li Zuofeng;Xu Ning;Guo Xiaojing;Zhang Huojun(Department of Radiation Oncology,Changhai Hospital of Naval Medical University,Shanghai 200433,China;Concord Medical Group,Beijing 100013,China;Varian Medical Systems,Beijing 100176,China;Department of Health Statistics,Faculty of Medical Services,Naval Medical University,Shanghai 200433,China)
出处 《中华放射医学与防护杂志》 CAS CSCD 北大核心 2022年第2期103-109,共7页 Chinese Journal of Radiological Medicine and Protection
基金 上海申康临床"五新"创新研发项目(SHDC2020CR3087B)。
关键词 胰腺癌 光子 质子 直线加速器 剂量分布 Pancreatic cancer Photon Proton Linear accelerator Dose distributions
  • 相关文献

参考文献3

二级参考文献20

  • 1Jennifer Y. Wo,Harvey J. Mamon,Cristina R. Ferrone,David P. Ryan,Lawrence S. Blaszkowsky,Eunice L. Kwak,Yolanda D. Tseng,Brian N. Napolitano,Marek Ancukiewicz,Richard S. Swanson,Keith D. Lillemoe,Carlos Fernandez-del Castillo,Theodore S. Hong.Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer[J].Radiotherapy and Oncology.2013
  • 2Kento Takatori,Kazuki Terashima,Rihito Yoshida,Aya Horai,Shinya Satake,Takayuki Ose,Naoto Kitajima,Yoshikazu Kinoshita,Yusuke Demizu,Nobukazu Fuwa.Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer[J].Journal of Gastroenterology.2014(6)
  • 3R. Charles Nichols,Thomas J. George,Robert A. Zaiden,Ziad T. Awad,Horacio J. Asbun,Soon Huh,Meng Wei Ho,Nancy P. Mendenhall,Christopher G. Morris,bradford S. Hoppe.Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity[J]. Acta Oncologica . 2013 (3)
  • 4Romaine C. Nichols,Soon N. Huh,Karl L. Prado,Byong Y. Yi,Navesh K. Sharma,Meng W. Ho,Bradford S. Hoppe,Nancy P. Mendenhall,Zuofeng Li,William F. Regine.Protons Offer Reduced Normal-Tissue Exposure for Patients Receiving Postoperative Radiotherapy for Resected Pancreatic Head Cancer[J]. International Journal of Radiation Oncology, Biology, Physics . 2012 (1)
  • 5Kazuki Terashima,Yusuke Demizu,Naoki Hashimoto,Dongcun Jin,Masayuki Mima,Osamu Fujii,Yasue Niwa,Kento Takatori,Naoto Kitajima,Sachiyo Sirakawa,Ku Yonson,Yoshio Hishikawa,Mitsuyuki Abe,Ryohei Sasaki,Kazuro Sugimura,Masao Murakami.A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis[J]. Radiotherapy and Oncology . 2012 (1)
  • 6Theodore S. Hong,David P. Ryan,Lawrence S. Blaszkowsky,Harvey J. Mamon,Eunice L. Kwak,Mari Mino-Kenudson,Judith Adams,Beow Yeap,Barbara Winrich,Thomas F. DeLaney,Carlos Fernandez-Del Castillo.Phase I Study of Preoperative Short-Course Chemoradiation With Proton Beam Therapy and Capecitabine for Resectable Pancreatic Ductal Adenocarcinoma of the Head[J]. International Journal of Radiation Oncology, Biology, Physics . 2011 (1)
  • 7Myriam Bouchard,Richard A. Amos,Tina M. Briere,Sam Beddar,Christopher H. Crane.Dose escalation with proton or photon radiation treatment for pancreatic cancer[J]. Radiotherapy and Oncology . 2009 (2)
  • 8Timothy M. Pawlik,Ana L. Gleisner,John L. Cameron,Jordan M. Winter,Lia Assumpcao,Keith D. Lillemoe,Christopher Wolfgang,Ralph H. Hruban,Richard D. Schulick,Charles J. Yeo,Michael A. Choti.Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer[J]. Surgery . 2007 (5)
  • 9Kevin R. Kozak,Lisa A. Kachnic,Judith Adams,Elizabeth M. Crowley,Brian M. Alexander,Harvey J. Mamon,Carlos Fernandez-Del Castillo,David P. Ryan,Thomas F. DeLaney,Theodore S. Hong.Dosimetric Feasibility of Hypofractionated Proton Radiotherapy for Neoadjuvant Pancreatic Cancer Treatment[J]. International Journal of Radiation Oncology, Biology, Physics . 2007 (5)
  • 10William F Regine,Kathryn A Winter,John P Hoffman,John P Hoffman,John P Hoffman,Al B Benson,Al B Benson,John S Macdonald,Tyvin A Rich,Christopher G Willett.Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial. Annals of Surgical Oncology . 2011

共引文献6

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部